These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24065278)

  • 41. Development of nonnucleoside HIV reverse transcriptase inhibitors.
    Tucker TJ; Lumma WC; Culberson JC
    Methods Enzymol; 1996; 275():440-72. PubMed ID: 9026654
    [No Abstract]   [Full Text] [Related]  

  • 42. Total synthesis and stereochemical assignment of baringolin.
    Just-Baringo X; Bruno P; Ottesen LK; Cañedo LM; Albericio F; Álvarez M
    Angew Chem Int Ed Engl; 2013 Jul; 52(30):7818-21. PubMed ID: 23780649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prospective CCR5 small molecule antagonist compound design using a combined mutagenesis/modeling approach.
    Metz M; Bourque E; Labrecque J; Danthi SJ; Langille J; Harwig C; Yang W; Darkes MC; Lau G; Santucci Z; Bridger GJ; Schols D; Fricker SP; Skerlj RT
    J Am Chem Soc; 2011 Oct; 133(41):16477-85. PubMed ID: 21942640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Syntheses and anti-HIV activities of (+/-)-norcarbovir and (+/-)-norabacavir.
    Huang W; Miller MJ; De Clercq E; Balzarini J
    Org Biomol Chem; 2007 Apr; 5(8):1164-6. PubMed ID: 17406712
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).
    Stupple PA; Batchelor DV; Corless M; Dorr PK; Ellis D; Fenwick DR; Galan SR; Jones RM; Mason HJ; Middleton DS; Perros M; Perruccio F; Platts MY; Pryde DC; Rodrigues D; Smith NN; Stephenson PT; Webster R; Westby M; Wood A
    J Med Chem; 2011 Jan; 54(1):67-77. PubMed ID: 21128663
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti human immunodeficiency virus-1 (HIV-1) agents 3. synthesis and in vitro anti-HIV-1 activity of some N-arylsulfonylindoles.
    Fan LL; Liu WQ; Xu H; Yang LM; Lv M; Zheng YT
    Chem Pharm Bull (Tokyo); 2009 Aug; 57(8):797-800. PubMed ID: 19652402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimization of unique, uncharged thioesters as inhibitors of HIV replication.
    Srivastava P; Schito M; Fattah RJ; Hara T; Hartman T; Buckheit RW; Turpin JA; Inman JK; Appella E
    Bioorg Med Chem; 2004 Dec; 12(24):6437-50. PubMed ID: 15556761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Derivatives of 2-mercaptobenzenesulphonamide. XIX. Syntheses, anticancer and anti-HIV activities of some 2-(4-chloro-2-mercaptobenzenesulphonylimino) perhydropyrimidines.
    Pomarnacka E
    Acta Pol Pharm; 1996; 53(5):373-8. PubMed ID: 9415213
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV-1 entry inhibitors: classes, applications and factors affecting potency.
    Sterjovski J; Churchill MJ; Wesselingh SL; Gorry PR
    Curr HIV Res; 2006 Oct; 4(4):387-400. PubMed ID: 17073614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-HIV activity of semisynthetic derivatives of andrographolide and computational study of HIV-1 gp120 protein binding.
    Uttekar MM; Das T; Pawar RS; Bhandari B; Menon V; Nutan ; Gupta SK; Bhat SV
    Eur J Med Chem; 2012 Oct; 56():368-74. PubMed ID: 22858223
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis and evaluation of small molecule CD4-mimics as entry inhibitors possessing broad spectrum anti-HIV-1 activity.
    Curreli F; Belov DS; Ramesh RR; Patel N; Altieri A; Kurkin AV; Debnath AK
    Bioorg Med Chem; 2016 Nov; 24(22):5988-6003. PubMed ID: 27707628
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
    Bollini M; Cisneros JA; Spasov KA; Anderson KS; Jorgensen WL
    Bioorg Med Chem Lett; 2013 Sep; 23(18):5213-6. PubMed ID: 23937980
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HIV co-receptor inhibitors as novel class of anti-HIV drugs.
    Schols D
    Antiviral Res; 2006 Sep; 71(2-3):216-26. PubMed ID: 16753228
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131.
    Tamamura H; Hiramatsu K; Ueda S; Wang Z; Kusano S; Terakubo S; Trent JO; Peiper SC; Yamamoto N; Nakashima H; Otaka A; Fujii N
    J Med Chem; 2005 Jan; 48(2):380-91. PubMed ID: 15658852
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-1 entry inhibitors: an overview.
    Kuritzkes DR
    Curr Opin HIV AIDS; 2009 Mar; 4(2):82-7. PubMed ID: 19339945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evolution of coreceptor utilization to escape CCR5 antagonist therapy.
    Zhang J; Gao X; Martin J; Rosa B; Chen Z; Mitreva M; Henrich T; Kuritzkes D; Ratner L
    Virology; 2016 Jul; 494():198-214. PubMed ID: 27128349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides.
    McCombie SW; Tagat JR; Vice SF; Lin SI; Steensma R; Palani A; Neustadt BR; Baroudy BM; Strizki JM; Endres M; Cox K; Dan N; Chou CC
    Bioorg Med Chem Lett; 2003 Feb; 13(3):567-71. PubMed ID: 12565973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 3: polar functionality and its effect on anti-HIV-1 activity.
    Hale JJ; Budhu RJ; Mills SG; MacCoss M; Gould SL; DeMartino JA; Springer MS; Siciliano SJ; Malkowitz L; Schleif WA; Hazuda D; Miller M; Kessler J; Danzeisen R; Holmes K; Lineberger J; Carella A; Carver G; Emini EA
    Bioorg Med Chem Lett; 2002 Oct; 12(20):2997-3000. PubMed ID: 12270192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Disulfide reshuffling triggers the release of a thiol-free anti-HIV agent to make up fast-acting, potent macromolecular prodrugs.
    Kock A; Zuwala K; Smith AA; Ruiz-Sanchis P; Wohl BM; Tolstrup M; Zelikin AN
    Chem Commun (Camb); 2014 Dec; 50(93):14498-500. PubMed ID: 25285337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1.
    Tallant MD; Duan M; Freeman GA; Ferris RG; Edelstein MP; Kazmierski WM; Wheelan PJ
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1394-8. PubMed ID: 21292480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.